<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03658590</url>
  </required_header>
  <id_info>
    <org_study_id>100</org_study_id>
    <nct_id>NCT03658590</nct_id>
  </id_info>
  <brief_title>Dexamethasone and Induction of Delivery</brief_title>
  <official_title>Dexamethasone Effect on Induction Delivery Interval at Term Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>samar sayed el sayed</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the effect of intravenous injection of a single dose of&#xD;
      dexamethasone in shortening the duration interval between initiation of labor induction and&#xD;
      delivery of the fetus in primigravida full-term pregnancy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Research hypothesis:&#xD;
&#xD;
      In full term primigravidae undergoing induction of labor, the use of a single dose of&#xD;
      dexamethasone (8mg) intra-venously will help in shortening the duration interval between&#xD;
      initiation of labor induction and delivery of the fetus.&#xD;
&#xD;
      Research question:&#xD;
&#xD;
      In full term primigravidae undergoing induction of labor, does the use of intra-venous&#xD;
      dexamethasone play a role in shortening the duration interval between initiation of labor&#xD;
      induction and delivery of the fetus?&#xD;
&#xD;
      Patients and Methods&#xD;
&#xD;
      Type of study:&#xD;
&#xD;
      Double blind randomized controlled trial.&#xD;
&#xD;
      Study settings:&#xD;
&#xD;
      Site: Ain Shams Maternity Hospital Study duration: 6 months&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      One hundred and two pregnant women will be recruited in this study from women attending the&#xD;
      emergency room department of obstetrics and gynecology at Ain Shams University.&#xD;
&#xD;
      Inclusion criteria:&#xD;
&#xD;
      Primiparity Singleton pregnancy Gestational age i.e. 40 weeks or more by date or 1st&#xD;
      trimestric ultrasound. Bishop score of 4 or greater. Longitudinal lie. Vertex presentation.&#xD;
      Intact membranes&#xD;
&#xD;
      Exclusion criteria:&#xD;
&#xD;
      Refused consent Malpresentation. Multiple pregnancies. Active phase of labour. Rupture of&#xD;
      membranes (ROM). Cephalo-pelvic disproportion. Previous C-section or myomectomy operation.&#xD;
      Known contraindication or hypersensitivity to Dexamethasone. Fetal distress. IUFD Current&#xD;
      maternal disorder e.g. diabetes mellitus and pregnancy induced hypertension.&#xD;
&#xD;
      Over distended abdomen e.g. fetal macrosomia or polyhydramonus suggested by ultrasound.&#xD;
&#xD;
      Ante-partum hemorrhage e.g. placenta previa, accidental hemorrhage.&#xD;
&#xD;
      These criteria will be assessed at first during the initial evaluation in the delivery suite&#xD;
      as follows:&#xD;
&#xD;
      History:&#xD;
&#xD;
      Personal, menstrual, obstetric, past and family history will be taken. History of present&#xD;
      pregnancy will be taken including the first day of last menstrual period, duration of&#xD;
      pregnancy, warning symptoms as headache, visual symptoms, edema of face and fingers,&#xD;
      excessive vomiting, heart burn, epigastric pain, vaginal bleeding, decreased fetal movements,&#xD;
      edema of the lower limbs and history of any drug intake.&#xD;
&#xD;
      Examination:&#xD;
&#xD;
        1. General examination:vital signs, chest, heart and lower limb examination.&#xD;
&#xD;
        2. Abdominal examination: for assessment of fundal level, presentation, expected fetal&#xD;
           weight, fetal heart rate and presence of scars of previous operations as cesarean&#xD;
           section or myomectomy.&#xD;
&#xD;
        3. Vaginal examination: for assessment of cervical dilatation and effacement at the&#xD;
           beginning, state of fetal membranes, station of fetal head, position of fetal head and&#xD;
           pelvic adequacy.&#xD;
&#xD;
      Investigations:&#xD;
&#xD;
        1. Laboratory: blood grouping, Rh typing, complete blood count.&#xD;
&#xD;
        2. Abdominal ultrasound: to confirm the gestational age, fetal number, viability,&#xD;
           presentation, position, estimated fetal weight, and to detect the grade of placental&#xD;
           maturity, amount and turbidity of liquor.&#xD;
&#xD;
        3. CTG: application of CTG half an hour to all participates before starting any&#xD;
           intervention.&#xD;
&#xD;
      Enrollment and Allocation of the patients:&#xD;
&#xD;
      After approval of health ethical committee in Ain Shams Hospital and after the initial&#xD;
      evaluation, women who fulfilled the appropriate inclusion and exclusion criteria will be&#xD;
      invited to participate in the study, a verbal consent will be obtained from each candidate&#xD;
      after explanation of the procedure in details.&#xD;
&#xD;
      Randomization:&#xD;
&#xD;
      The eligible 102 women will be randomized into one of the following two groups:&#xD;
&#xD;
        1. Group D (study group): including 51 women who will receive a prefilled syringe with two&#xD;
           milliliters (8 mg) of dexamethasone intravenously.&#xD;
&#xD;
        2. Group P (control group): including 51 women who will receive a prefilled syringe with&#xD;
           two milliliters of distilled water intravenously.&#xD;
&#xD;
      No cervical ripping agent will be used for induction of labor in either group. Randomization&#xD;
      is performed using a computer-generated randomization system. 102 opaque envelopes will be&#xD;
      numbered serially; each envelope will contain the corresponding letter in the randomization&#xD;
      table, and when the first pregnant woman arrived, the first envelope will be opened and the&#xD;
      pregnant woman will be allocated to the group according to the inside letter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">June 30, 2018</completion_date>
  <primary_completion_date type="Actual">April 15, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The interval between the initiation of induction and the delivery of the fetus.</measure>
    <time_frame>Up to 1 day</time_frame>
    <description>Mean time of interval between the initiation of induction and the delivery of the fetus in the two groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The duration of the first stage of labor (Partographic representation will do for each participant).</measure>
    <time_frame>Up to 1 hour</time_frame>
    <description>Mean time of duration of the first stage of labor in the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The duration of the second stage of labor.</measure>
    <time_frame>Up to 2 hours</time_frame>
    <description>Mean time of duration of the second stage of labor in the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The duration of the third stage of labor.</measure>
    <time_frame>Up to 30 minutes</time_frame>
    <description>Mean time of duration of the third stage of labor in the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The neonatal outcome by APGAR score.</measure>
    <time_frame>at 1 and 5 minutes</time_frame>
    <description>Mean of APGAR score at 1 and 5 minutes for fetus in the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any postpartum maternal adverse effects (e.g. vital sing abnormality, any maternal postpartum hemorrhage and central nervous system manifestation).</measure>
    <time_frame>Up to 1 day</time_frame>
    <description>Percentage of postpartum adverse effects in both group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Induction of Labor Affected Fetus / Newborn</condition>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>including 51 women who will receive a prefilled syringe with two milliliters (8 mg) of dexamethasone intravenously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>including 51 women who will receive a prefilled syringe with two milliliters of distilled water intravenously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>a prefilled syringe with two milliliters (8 mg) of dexamethasone intravenously</description>
    <arm_group_label>Group D</arm_group_label>
    <other_name>Drug group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Distilled Water</intervention_name>
    <description>a prefilled syringe with two milliliters of distilled water intravenously.</description>
    <arm_group_label>Group P</arm_group_label>
    <other_name>Placebo group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primiparity&#xD;
&#xD;
          -  Singleton pregnancy&#xD;
&#xD;
          -  Gestational age i.e. 40 weeks or more by date or 1sttrimestric ultrasound.&#xD;
&#xD;
          -  Bishop score of 4 or greater.&#xD;
&#xD;
          -  Longitudinal lie.&#xD;
&#xD;
          -  Vertex presentation.&#xD;
&#xD;
          -  Intact membranes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refused consent&#xD;
&#xD;
          -  Malpresentation.&#xD;
&#xD;
          -  Multiple pregnancies.&#xD;
&#xD;
          -  Active phase of labour.&#xD;
&#xD;
          -  Rupture of membranes (ROM).&#xD;
&#xD;
          -  Cephalo-pelvic disproportion.&#xD;
&#xD;
          -  Previous C-section or myomectomy operation.&#xD;
&#xD;
          -  Known contraindication or hypersensitivity to Dexamethasone.&#xD;
&#xD;
          -  Fetal distress.&#xD;
&#xD;
          -  IUFD&#xD;
&#xD;
          -  Current maternal disorder e.g. diabetes mellitus and pregnancy induced hypertension.&#xD;
&#xD;
          -  Over distended abdomen e.g. fetal macrosomia or polyhydramonus suggested by&#xD;
             ultrasound.&#xD;
&#xD;
          -  Ante-partum hemorrhage e.g. placenta previa, accidental hemorrhage.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tarek F Tamara, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amgad E Abou Gamrah, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gihan E Elhawwary, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ain Shams University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>August 29, 2018</study_first_submitted>
  <study_first_submitted_qc>September 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2018</study_first_posted>
  <last_update_submitted>September 2, 2018</last_update_submitted>
  <last_update_submitted_qc>September 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>samar sayed el sayed</investigator_full_name>
    <investigator_title>Gynecologist and Obstetrician</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

